Investor Area

Home / Investor Area / Financial Overview

Financial Overview

CLINUVEL’s end of financial year is 30 June.

5 Year Financial Summary

As at 30 June
2019
2018
2017
2016
2015
Profit & Loss
Revenues
A$m
32.5
26.2
17.3
7.2
3.7
Expenses
A$m
14.4
13.3
10.1
10.4
14.1
Net Profit / (Loss)
A$m
18.1
13.2
7.1
(3.2)
(10.4)
Balance Sheet
Cash and Cash Equivalents
A$m
54.3
36.2
23.8
13.8
10.6
Total Assets
A$m
62.3
42.9
28.6
20.1
13.6
Total Liabilities
A$m
5.2
3.5
3.1
2.3
2.4
Equity
A$m
57.2
39.4
25.4
17.8
11.2
Cash Flow
Cashflows From (Used In) Operating Activities
A$m
18.4
11.7
9.9
(5.0)
(4.5)
Net Increase in Cash Held
A$m
17.2
11.6
9.9
3.3
(4.3)
Key Variables
Basic Earnings Per Share
Cents
37.6
27.7
14.9
(7.0)
(24.0)
Net Tangible Assets Backing
A$ per share
1.2
0.8
0.5
0.4
0.3
Return on Equity
%
32
34
28.0

Some figures in the table may vary slightly to CLINUVEL’s reporting due to rounding. Please consult our Announcements page for Annual Reports.

Please refer to the Announcements Calendar for planned financial releases.

CLINUVEL has raised over A$95.0 million since 2006 to fund its clinical programme for afamelonotide.

Capital Raisings

Capital Raisings (Since Jan ’06)
$m Raised
# Shares (m)
*Price*
May 2006 Placement
$5.0
1.5
$3.41
Sep 2006 Rights Issue and Placement
$35.2
9.1
$3.85
Apr 2007 Placement
$26.0
2.4
$10.70
Jun 2012 Placement
$6.0
3.4
$1.75
May 2013 Placement
$6.3
2.98
$2.136
Jun 2014 Placement
$7.2
4.17
$1.658
Mar 2016 Placement
$8.3
2.53
$3.30

* Represented at post-consolidated basis after capital re-organisation November 2010 (10:1 Reverse Stock Split).

Page last updated 28 August 2019